Human Herpes Virus 6B in Mesial Temporal Lobe Epilepsy

Author(s):  
Pitt Niehusmann ◽  
Jin-Mei Li ◽  
Dong Zhou
Epilepsia ◽  
2010 ◽  
Vol 51 (12) ◽  
pp. 2478-2483 ◽  
Author(s):  
Pitt Niehusmann ◽  
Tobias Mittelstaedt ◽  
Christian G. Bien ◽  
Jan F. Drexler ◽  
Alexander Grote ◽  
...  

2021 ◽  
Vol 3 (1) ◽  
Author(s):  
Jiaqi Wang ◽  
Jinmei Li

AbstractHuman herpes virus 6 (HHV-6) is a ubiquitous and most common pathogen that affects humans. Human herpes virus 6B (HHV-6B) is a wide spread human herpesvirus that infects most people when they are children, establishes latent infections in the central nervous system (CNS), especially in the hippocampus and amygdala, and induces neurologic diseases. HHV-6 can establish a latent infection and be reactivated by various stimuli. Recently, viral genomic DNA of HHV-6B has been detected in surgically removed brain tissues of intractable epilepsy patients, suggesting the involvement of HHV-6B in the pathogenesis of epilepsy. Temporal lobe epilepsy (TLE) has been shown to be closely related with HHV-6B. TLE patients with HHV-6B in their brains suffer from reiterative attacks of febrile seizures and hippocampal sclerosis. However, the mechanisms underlying the contribution of this virus to the development of TLE remains unknown. The direct damage and immune activation caused by the virus are involved in the process of neuron damage, abnormal neural circuit formation and glial cell proliferation. In addition, some cytokines like interleukin-17A (IL-17A), nuclear factor-kappa B (NF-κb), transforming growth factor-β (TGF-β), mitogen-activated protein kinase (MAPK) and phospholipase A2 are up-regulated and involved in the pathological process of TLE. More studies are needed to clarify the mechanisms underlying the link between HHV-6B and epilepsy, and identify biomarkers to recognize different patient groups for anti-inflammatory or immunomodulatory therapies.


Sign in / Sign up

Export Citation Format

Share Document